ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SMMT Summit Therapeutics Inc

9.36
-0.11 (-1.16%)
Last Updated: 17:45:38
Delayed by 15 minutes
Name Symbol Market Type
Summit Therapeutics Inc NASDAQ:SMMT NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.11 -1.16% 9.36 9.34 9.36 9.78 9.21 9.53 1,517,095 17:45:38

Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2017 on 14 June 2017

13/06/2017 12:00pm

GlobeNewswire Inc.


Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Summit Therapeutics Charts.

Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for the first quarter ended 30 April 2017 on 14 June 2017.

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

-END-

For more information, please contact: 

Summit Therapeutics
Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski / Michelle Avery (US office)
Tel: +44 (0)1235 443 951
       +1 617 225 4455

Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson
Tel: +44 (0)20 7213 0880

N+1 Singer 
(Broker)
Aubrey Powell / Lauren Kettle	
Tel: +44 (0)20 7496 3000

MacDougall Biomedical Communications
(US media contact)
Karen Sharma
Tel: +1 781 235 3060
ksharma@macbiocom.com 

Consilium Strategic Communications
(Financial public relations, UK)
Mary-Jane Elliott / Sue Stuart / 
Jessica Hodgson / Lindsey Neville	
Tel: +44 (0)20 3709 5700
summit@consilium-comms.com 

1 Year Summit Therapeutics Chart

1 Year Summit Therapeutics Chart

1 Month Summit Therapeutics Chart

1 Month Summit Therapeutics Chart

Your Recent History